sotagliflozin + sitagliptin

Sotagliflozin + sitagliptin is an experimental oral fixed-dose combination of two small-molecule agents for treating type 2 diabetes mellitus. **Sotagliflozin** is a dual inhibitor of sodium–glucose co-transporter 2 (SGLT2) and sodium–glucose co-transporter 1 (SGLT1), lowering blood glucose by promoting urinary glucose excretion (via SGLT2 inhibition in the kidney) and delaying glucose absorption in the intestine (via SGLT1 inhibition), which also increases endogenous incretin (GLP-1, PYY) secretion[1][2][3][4]. **Sitagliptin** is a selective dipeptidyl peptidase-4 (DPP-4) inhibitor, which improves glycemic control by preventing GLP-1 and GIP inactivation, enhancing glucose-dependent insulin secretion and reducing glucagon secretion[5]. When administered together, these agents demonstrate a synergistic elevation of active GLP-1 and improved glycemic profiles with reduced insulin requirements compared to either agent alone in type 2 diabetes, suggesting enhanced benefit over monotherapy[1][3].